Tirzepatide can indirectly affect your period, primarily through weight loss rather than any direct hormonal mechanism
Amycretin, a single molecule that combines GLP-1 and amylin activity in both oral and injectable forms, and survodutide, a GLP-1 and glucagon agonist aimed heavily at liver disease, have both advanced into Phase 3
This is what is known as a ghost trial: a study that was registered, conducted, and then never reported
Obesity is especially pervasive across our country as rates continue to rise here in the US and around the world, said David Ricks, CEO of chair of Lilly during a live presentation in Kenosha County
Using CATE values to divide the combined study cohorts with estimator information (46,394 individuals) into sub-cohorts revealed that those with a greater estimated glycemic advantage with glucagon-lile-peptide-1 receptor agonists over SGLT2 inhibitors were predominantly older and female, with lower initial HbA1c, body mass index (BMI), and estimated glomerular filtration rate (eGFR)
Weight loss can happen, but it is usually considered a secondary benefit rather than the main reason it is prescribed
